Adalimumab, Infliximab And Etanercept Biosimilars Market Report

Global and Region Adalimumab, Infliximab And Etanercept Biosimilars Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 01, 2022
  • PAGES：206
  • REPORT CODE：GMM968069
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Adalimumab, Infliximab And Etanercept Biosimilars market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Adalimumab, Infliximab And Etanercept Biosimilarsmarket, defines the market attractiveness level of Adalimumab, Infliximab And Etanercept Biosimilars market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Adalimumab, Infliximab And Etanercept Biosimilars industry, describes the types of Adalimumab, Infliximab And Etanercept Biosimilars market, the applications of major players and the market size, and deeply analyzes the current situation of the global Adalimumab, Infliximab And Etanercept Biosimilars market and the development prospects and opportunities of Adalimumab, Infliximab And Etanercept Biosimilars industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Adalimumab, Infliximab And Etanercept Biosimilars market in Chapter 13.

    By Player:

    • Cipla

    • Samsung Bioepis(Samsung Biologics)

    • Coherus BioSciences

    • Amgen

    • Pfizer

    • Hetero

    • Hetero Labs

    • Mylan

    • Fresenius Kabi

    • Novartis

    • Celltrion

    • Boehringer Ingelheim

    By Type:

    • Adalimumab Biosimilars

    • Infliximab Biosimilars

    • Etanercept Biosimilars

    By End-User:

    • Hospital Pharmacies

    • Retail Pharmacies

    • Online Pharmacies

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Adalimumab, Infliximab And Etanercept Biosimilars Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Adalimumab, Infliximab And Etanercept Biosimilars Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Adalimumab, Infliximab And Etanercept Biosimilars Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Adalimumab, Infliximab And Etanercept Biosimilars Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Adalimumab, Infliximab And Etanercept Biosimilars Market Analysis and Outlook to 2022

    • 7.1 Global Adalimumab, Infliximab And Etanercept Biosimilars Consumption (2017-2022)

    • 7.2 United States Adalimumab, Infliximab And Etanercept Biosimilars Consumption (2017-2022)

    • 7.3 Europe Adalimumab, Infliximab And Etanercept Biosimilars Consumption (2017-2022)

    • 7.4 China Adalimumab, Infliximab And Etanercept Biosimilars Consumption (2017-2022)

    • 7.5 Japan Adalimumab, Infliximab And Etanercept Biosimilars Consumption (2017-2022)

    • 7.6 India Adalimumab, Infliximab And Etanercept Biosimilars Consumption (2017-2022)

    • 7.7 South Korea Adalimumab, Infliximab And Etanercept Biosimilars Consumption (2017-2022)

    8 Region and Country-wise Adalimumab, Infliximab And Etanercept Biosimilars Market Analysis and Outlook to 2028

    • 8.1 Global Adalimumab, Infliximab And Etanercept Biosimilars Consumption Forecast (2022-2028)

    • 8.2 United States Adalimumab, Infliximab And Etanercept Biosimilars Consumption Forecast (2022-2028)

    • 8.3 Europe Adalimumab, Infliximab And Etanercept Biosimilars Consumption Forecast (2022-2028)

    • 8.4 China Adalimumab, Infliximab And Etanercept Biosimilars Consumption Forecast (2022-2028)

    • 8.5 Japan Adalimumab, Infliximab And Etanercept Biosimilars Consumption Forecast (2022-2028)

    • 8.6 India Adalimumab, Infliximab And Etanercept Biosimilars Consumption Forecast (2022-2028)

    • 8.7 South Korea Adalimumab, Infliximab And Etanercept Biosimilars Consumption Forecast (2022-2028)

    9 Global Adalimumab, Infliximab And Etanercept Biosimilars Market Outlook by Types and Applications to 2022

    • 9.1 Global Adalimumab, Infliximab And Etanercept Biosimilars Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Adalimumab Biosimilars Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Infliximab Biosimilars Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Etanercept Biosimilars Consumption and Growth Rate (2017-2022)

    • 9.2 Global Adalimumab, Infliximab And Etanercept Biosimilars Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Retail Pharmacies Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Online Pharmacies Consumption and Growth Rate (2017-2022)

    10 Global Adalimumab, Infliximab And Etanercept Biosimilars Market Outlook by Types and Applications to 2028

    • 10.1 Global Adalimumab, Infliximab And Etanercept Biosimilars Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Adalimumab Biosimilars Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Infliximab Biosimilars Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Etanercept Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Adalimumab, Infliximab And Etanercept Biosimilars Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    11 Global Adalimumab, Infliximab And Etanercept Biosimilars Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Adalimumab, Infliximab And Etanercept Biosimilars Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Adalimumab, Infliximab And Etanercept Biosimilars Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Adalimumab, Infliximab And Etanercept Biosimilars Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Adalimumab, Infliximab And Etanercept Biosimilars Market Competitive Analysis

    • 14.1 Cipla

      • 14.1.1 Cipla Company Details

      • 14.1.2 Cipla Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Cipla Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • 14.2 Samsung Bioepis(Samsung Biologics)

      • 14.2.1 Samsung Bioepis(Samsung Biologics) Company Details

      • 14.2.2 Samsung Bioepis(Samsung Biologics) Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Samsung Bioepis(Samsung Biologics) Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • 14.3 Coherus BioSciences

      • 14.3.1 Coherus BioSciences Company Details

      • 14.3.2 Coherus BioSciences Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Coherus BioSciences Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • 14.4 Amgen

      • 14.4.1 Amgen Company Details

      • 14.4.2 Amgen Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Amgen Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • 14.5 Pfizer

      • 14.5.1 Pfizer Company Details

      • 14.5.2 Pfizer Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Pfizer Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • 14.6 Hetero

      • 14.6.1 Hetero Company Details

      • 14.6.2 Hetero Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Hetero Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • 14.7 Hetero Labs

      • 14.7.1 Hetero Labs Company Details

      • 14.7.2 Hetero Labs Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Hetero Labs Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • 14.8 Mylan

      • 14.8.1 Mylan Company Details

      • 14.8.2 Mylan Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Mylan Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • 14.9 Fresenius Kabi

      • 14.9.1 Fresenius Kabi Company Details

      • 14.9.2 Fresenius Kabi Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Fresenius Kabi Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • 14.10 Novartis

      • 14.10.1 Novartis Company Details

      • 14.10.2 Novartis Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Novartis Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • 14.11 Celltrion

      • 14.11.1 Celltrion Company Details

      • 14.11.2 Celltrion Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Celltrion Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • 14.12 Boehringer Ingelheim

      • 14.12.1 Boehringer Ingelheim Company Details

      • 14.12.2 Boehringer Ingelheim Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Boehringer Ingelheim Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Adalimumab, Infliximab And Etanercept Biosimilars

    • Figure Adalimumab, Infliximab And Etanercept Biosimilars Picture

    • Table Global Adalimumab, Infliximab And Etanercept Biosimilars Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Adalimumab, Infliximab And Etanercept Biosimilars Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Adalimumab, Infliximab And Etanercept Biosimilars Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Adalimumab, Infliximab And Etanercept Biosimilars Consumption by Country (2017-2022)

    • Figure United States Adalimumab, Infliximab And Etanercept Biosimilars Consumption and Growth Rate (2017-2022)

    • Table Europe Adalimumab, Infliximab And Etanercept Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure China Adalimumab, Infliximab And Etanercept Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Japan Adalimumab, Infliximab And Etanercept Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure India Adalimumab, Infliximab And Etanercept Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure South Korea Adalimumab, Infliximab And Etanercept Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Global Adalimumab, Infliximab And Etanercept Biosimilars Consumption Forecast by Country (2022-2028)

    • Figure United States Adalimumab, Infliximab And Etanercept Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Adalimumab, Infliximab And Etanercept Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Adalimumab, Infliximab And Etanercept Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Adalimumab, Infliximab And Etanercept Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Adalimumab, Infliximab And Etanercept Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Adalimumab, Infliximab And Etanercept Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Adalimumab Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Global Infliximab Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Global Etanercept Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)

    • Figure Global Retail Pharmacies Consumption and Growth Rate (2017-2022)

    • Figure Global Online Pharmacies Consumption and Growth Rate (2017-2022)

    • Figure Global Adalimumab Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Infliximab Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Etanercept Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Adalimumab, Infliximab And Etanercept Biosimilars Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Adalimumab, Infliximab And Etanercept Biosimilars Export by Region (Top 5 Countries) (2017-2028)

    • Table Cipla (Foundation Year, Company Profile and etc.)

    • Table Cipla Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cipla Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • Table Samsung Bioepis(Samsung Biologics) (Foundation Year, Company Profile and etc.)

    • Table Samsung Bioepis(Samsung Biologics) Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Samsung Bioepis(Samsung Biologics) Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • Table Coherus BioSciences (Foundation Year, Company Profile and etc.)

    • Table Coherus BioSciences Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Coherus BioSciences Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • Table Amgen (Foundation Year, Company Profile and etc.)

    • Table Amgen Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amgen Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • Table Hetero (Foundation Year, Company Profile and etc.)

    • Table Hetero Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hetero Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • Table Hetero Labs (Foundation Year, Company Profile and etc.)

    • Table Hetero Labs Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hetero Labs Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • Table Mylan (Foundation Year, Company Profile and etc.)

    • Table Mylan Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mylan Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • Table Fresenius Kabi (Foundation Year, Company Profile and etc.)

    • Table Fresenius Kabi Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Fresenius Kabi Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • Table Novartis (Foundation Year, Company Profile and etc.)

    • Table Novartis Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • Table Celltrion (Foundation Year, Company Profile and etc.)

    • Table Celltrion Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celltrion Adalimumab, Infliximab And Etanercept Biosimilars Product and Service

    • Table Boehringer Ingelheim (Foundation Year, Company Profile and etc.)

    • Table Boehringer Ingelheim Adalimumab, Infliximab And Etanercept Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer Ingelheim Adalimumab, Infliximab And Etanercept Biosimilars Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US